Tranilast

• Background:

  Tranilast is an antiallergic, antifibrotic drug that inhibits collagen synthesis, when administered in a dose –dependent manner for a 48 h treatment (1). As an antifibrotic agent, studies shown an effect on the growth of metastasis of mammary carcinoma. It is associated with the inhibition of the growth factor –beta. (TGF-beta) (2).

• Description:

  Angiogenesis inhibitor

• Product Name Alternative:

  2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2- enoyl]amino}benzoic acid

• UNSPSC:

  41116105

• Source:

  Synthetic

• Purity:

  ≥95% (HPLC)

• Weight:

  0.01

• Format:

  Off-white to yellow powder.

• Solubility:

  Soluble in DMSO.

• Molecular Formula:

  C18H17NO5

• Molecular Weight:

  327.33

• Precautions:

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations:

  1. Yamada H., Tajima S., Nishikawa T., Murad S., and Pinnell S., (1999) The Journal of Biochemistrystry. 116(4): 892-897. 2. Chakrabarti R., Subramanian V., Abadalla J., Jothy S., Predhomme GJ. (2009) Anticancer Drugs. 20(5): 334-45.

• CAS Number:

  53902-12-8